Heron Therapeutics (HRTX) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a sell rating to a hold rating in a research report released on Wednesday.

Several other research analysts have also commented on HRTX. Oppenheimer set a $27.00 price objective on Heron Therapeutics and gave the company a buy rating in a research report on Thursday, December 14th. Mizuho began coverage on Heron Therapeutics in a research note on Tuesday, September 26th. They set a buy rating and a $28.00 target price for the company. Northland Securities began coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They set an outperform rating and a $40.00 target price for the company. Noble Financial restated a buy rating and set a $24.00 target price on shares of Heron Therapeutics in a research note on Friday, October 6th. Finally, Cowen restated a buy rating and set a $40.00 target price on shares of Heron Therapeutics in a research note on Wednesday, December 6th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $28.73.

Heron Therapeutics (NASDAQ HRTX) opened at $18.35 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $18.65. The company has a market capitalization of $1,132.76, a PE ratio of -4.84 and a beta of 2.13.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. equities research analysts anticipate that Heron Therapeutics will post -3.41 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in HRTX. Legal & General Group Plc grew its stake in Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares in the last quarter. Quantbot Technologies LP grew its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 12,024 shares in the last quarter. Trexquant Investment LP acquired a new position in Heron Therapeutics in the third quarter worth about $206,000. Jane Street Group LLC acquired a new position in Heron Therapeutics in the third quarter worth about $223,000. Finally, HighTower Advisors LLC grew its stake in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares in the last quarter. Institutional investors own 98.78% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics (HRTX) Raised to “Hold” at BidaskClub” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/24/heron-therapeutics-hrtx-raised-to-hold-at-bidaskclub.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

What are top analysts saying about Heron Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit